Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Ho

Showing results (41-50 of 143) with videos related to

Pageof 15
Sort By:
STAR Protocols|November 26, 2021
Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse modelsNan Li, Rosa Nguyen, Carol J Thiele, et al.
Pharmacology & Therapeutics|May 16, 2021
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3Nan Li, Madeline R Spetz, Dan Li, et al.
Proteoglycan Research|January 17, 2025
A proteomic atlas of glypican-3 interacting partners: Identification of alpha-fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancerYi-Fan Zhang, Shaoli Lin, Xiao Zhen, et al.
The Journal of Biological Chemistry|October 20, 2004
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxinMitchell Ho, Robert J Kreitman, Masanori Onda, et al.
Current Protocols|January 3, 2023
Humanization of the Shark V<sub>NAR</sub> Single Domain Antibody Using CDR GraftingYi-Fan Zhang, Yaping Sun, Jessica Hong, et al.
Trends in Cancer|October 25, 2018
Glypicans as Cancer Therapeutic TargetsNan Li, Wei Gao, Yi-Fan Zhang, et al.
Antibody Therapeutics|December 18, 2019
Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the ClinicHong Li, You Li, Cheng Wang, et al.
Seminars in Immunology|March 12, 2026
Chimeric antigen receptor therapy for hepatocellular carcinomaLorenz Kocheise, Mohamed-Reda Benmebarek, Mitchell Ho, et al.
Oncotarget|July 16, 2016
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapyChunguang Wang, Wei Gao, Mingqian Feng, et al.
Antibody Therapeutics|October 27, 2022
The emergence of AntibodyPlus: the future trend of antibody-based therapeuticsYong Zhu, Shawn Shouye Wang, Zhaohui Sunny Zhou, et al.
Pageof 15

Showing results (41-50 of 143) with videos related to

Sort By:
Pageof 15
STAR Protocols|November 26, 2021
Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse modelsNan Li, Rosa Nguyen, Carol J Thiele, et al.
Pharmacology & Therapeutics|May 16, 2021
Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3Nan Li, Madeline R Spetz, Dan Li, et al.
Proteoglycan Research|January 17, 2025
A proteomic atlas of glypican-3 interacting partners: Identification of alpha-fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancerYi-Fan Zhang, Shaoli Lin, Xiao Zhen, et al.
The Journal of Biological Chemistry|October 20, 2004
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxinMitchell Ho, Robert J Kreitman, Masanori Onda, et al.
Current Protocols|January 3, 2023
Humanization of the Shark V<sub>NAR</sub> Single Domain Antibody Using CDR GraftingYi-Fan Zhang, Yaping Sun, Jessica Hong, et al.
Trends in Cancer|October 25, 2018
Glypicans as Cancer Therapeutic TargetsNan Li, Wei Gao, Yi-Fan Zhang, et al.
Antibody Therapeutics|December 18, 2019
Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the ClinicHong Li, You Li, Cheng Wang, et al.
Seminars in Immunology|March 12, 2026
Chimeric antigen receptor therapy for hepatocellular carcinomaLorenz Kocheise, Mohamed-Reda Benmebarek, Mitchell Ho, et al.
Oncotarget|July 16, 2016
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapyChunguang Wang, Wei Gao, Mingqian Feng, et al.
Antibody Therapeutics|October 27, 2022
The emergence of AntibodyPlus: the future trend of antibody-based therapeuticsYong Zhu, Shawn Shouye Wang, Zhaohui Sunny Zhou, et al.
Pageof 15